Aclaris Therapeutics (ACRS) Preferred Stock Liabilities (2014 - 2015)
Aclaris Therapeutics' (ACRS) quarterly Preferred Stock Liabilities came in at $78.3 million in Q3 2015, up 113.5% quarter-over-quarter from $36.7 million in Q4 2014.
Aclaris Therapeutics (ACRS) Preferred Stock Liabilities (2014 - 2015) Analysis & Trends
Aclaris Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $78.3 million for Q3 2015.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $78.3 million in Q3 2015; TTM through Sep 2015 was $78.3 million, a N/A change from a year earlier, with the FY2014 full-year figure at $36.7 million, up 59.47% from the prior year.
- Preferred Stock Liabilities improved to $78.3 million in Q3 2015 per ACRS's latest filing, from $36.7 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $78.3 million in Q3 2015 and bottomed at $36.7 million in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aclaris Therapeutics | 705.88 Mn | 705.88 Mn | 1.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 78.31 Mn |
| Dec 31, 2014 | 36.68 Mn |